Bradley S Quon
Overview
Explore the profile of Bradley S Quon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
1221
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gravelle J, Desai S, Dong K, Quon B
J Cyst Fibros
. 2025 Mar;
PMID: 40074570
Fatigue is common among adults with cystic fibrosis (awCF) and may be associated with systemic inflammation. This study examines systemic inflammation, measured by C-reactive protein (CRP), and fatigue, assessed using...
2.
3.
4.
Love A, Desai S, Cheng S, Stephenson A, Stanojevic S, Franciosi A, et al.
Ann Am Thorac Soc
. 2024 Oct;
22(2):302-305.
PMID: 39480171
No abstract available.
5.
Pichler V, Dalkilic L, Shoaib G, Shapira T, Rankine-Wilson L, Boudehen Y, et al.
J Med Microbiol
. 2024 Aug;
73(8).
PMID: 39158416
(MABS) is a pathogenic bacterium that can cause severe lung infections, particularly in individuals with cystic fibrosis. MABS colonies can exhibit either a smooth (S) or rough (R) morphotype, influenced...
6.
Dong K, Jang J, Shannon C, Ng R, Tebbutt S, Quon B
Ann Am Thorac Soc
. 2024 Aug;
21(12):1688-1697.
PMID: 39137349
The factors that lead to poor pulmonary exacerbation (PEx) outcomes in individuals with cystic fibrosis (CF) are still being investigated; however, delayed diagnosis and treatment are likely contributory. Identifying individuals...
7.
Laflamme O, Johnson N, Steele K, Chavez L, Cheng S, Rabin H, et al.
BMJ Open Respir Res
. 2024 Aug;
11(1).
PMID: 39122474
Background: Cost of illness studies are important tools to summarise the burden of disease for individuals, the healthcare system and society. The lack of standardised methods for reporting costs for...
8.
Lupas D, Chou F, Hakani M, Kuthiala I, Srikrishnaraj A, Li X, et al.
J Cyst Fibros
. 2024 Jul;
23(5):950-958.
PMID: 39048464
Background: Access to elexacaftor/tezacaftor/ivacaftor (ETI) for people with cystic fibrosis (PwCF) without a F508del variant is limited due to lack of clinical data supporting efficacy. Methods: In this systematic review...
9.
Nguyen M, MacDiarmid P, Tanzler A, Dagenais R, Bevanda C, Quon B
J Cyst Fibros
. 2024 Jul;
24(1):26-29.
PMID: 39034264
The mental health effects of elexacaftor/tezacaftor/ivacaftor (ETI) on adults with CF are still uncertain with mixed findings from published studies. To systematically investigate the impact of ETI on symptoms of...
10.
Waters V, Shaw M, Perrem L, Quon B, Tullis E, Solomon M, et al.
Eur Respir J
. 2024 May;
63(6).
PMID: 38697648
Background: Elevated markers of systemic and pulmonary inflammation are associated with failure to recover lung function following pulmonary exacerbations in people with cystic fibrosis (pwCF). Our aim was to determine...